Payment overview · 2025
General Payments
$520.01
23 reported records · 13 companies
Healthcare provider profile · identity verified
Gregory J Dilorenzo, D.O
Allopathic & Osteopathic Physicians|Internal Medicine · BROOMFIELD, CO · NPI 1861404048
Verified facts
What the public records show
CMS Open Payments records show Gregory J Dilorenzo, D.O received $520.01 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $117.18 | 22.5% | 6 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $57.91 | 11.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.54 | 10.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.32 | 9.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.01 | 9.4% | 3 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $41.23 | 7.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $30.70 | 5.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.64 | 4.7% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.63 | 4.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.25 | 3.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.60 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.63 | 3.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.37 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $520.01 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $57.91 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $57.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $57.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $57.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.54 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.47 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $41.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.67 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $30.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
186 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 645 | 228 |
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 194 |
| Lisinopril | Lisinopril | 396 | 145 |
| Losartan Potassium | Losartan Potassium | 344 | 114 |
| Omeprazole | Omeprazole | 265 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 250 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 85 |
| Gabapentin | Gabapentin | 189 | 62 |
| Eliquis | Apixaban | 186 | 40 |
| Finasteride | Finasteride | 178 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 60 |
| Simvastatin | Simvastatin | 174 | 58 |
| Furosemide | Furosemide | 162 | 60 |
| Allopurinol | Allopurinol | 160 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 55 |
| Metformin Hcl | Metformin Hcl | 154 | 64 |
| Potassium Chloride | Potassium Chloride | 151 | 55 |
| Metformin Hcl Er | Metformin Hcl | 149 | 53 |
| Alprazolam | Alprazolam | 120 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 37 |
| Trazodone Hcl | Trazodone Hcl | 108 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 50 |
| Doxazosin Mesylate | Doxazosin Mesylate | 103 | 30 |
| Montelukast Sodium | Montelukast Sodium | 100 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 56 |
| Tramadol Hcl | Tramadol Hcl | 96 | 22 |
| Alendronate Sodium | Alendronate Sodium | 95 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 28 |
| Famotidine | Famotidine | 87 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 22 |
| Lovastatin | Lovastatin | 79 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 20 |
| Jardiance | Empagliflozin | 75 | 24 |
| Januvia | Sitagliptin Phosphate | 72 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 22 |
| Trulicity | Dulaglutide | 71 | 15 |
| Warfarin Sodium | Warfarin Sodium | 69 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 22 |
| Ozempic | Semaglutide | 66 | 23 |
| Donepezil Hcl | Donepezil Hcl | 63 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 22 |
| Spironolactone | Spironolactone | 58 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 15 |
| Atenolol | Atenolol | 49 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Sertraline Hcl | Sertraline Hcl | 48 | 17 |
| Fenofibrate | Fenofibrate | 47 | 16 |
| Myrbetriq | Mirabegron | 47 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 14 |
| Ezetimibe | Ezetimibe | 40 | 16 |
| Synthroid | Levothyroxine Sodium | 40 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 13 |
| Amoxicillin | Amoxicillin | 38 | 31 |
| Glipizide Er | Glipizide | 38 | 11 |
| Mounjaro | Tirzepatide | 38 | 12 |
| Xarelto | Rivaroxaban | 38 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 19 |
| Lorazepam | Lorazepam | 35 | 16 |
| Fluconazole | Fluconazole | 34 | 17 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 27 |
| Carvedilol | Carvedilol | 30 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 11 |
| Clonidine Hcl | Clonidine Hcl | 28 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 14 |
| Nateglinide | Nateglinide | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | 11 |
| Temazepam | Temazepam | 28 | suppressed |
| Ciclopirox | Ciclopirox | 27 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 20 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Colchicine | Colchicine | 25 | 12 |
| Estradiol | Estradiol | 25 | 14 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 13 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Prednisone | Prednisone | 21 | 18 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Diazepam | Diazepam | 20 | 11 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Dutasteride | Dutasteride | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Imiquimod | Imiquimod | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520.01 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, CAPVAXIVE, CHARTIS CATHETER, Cologuard Collection Kit, EVENITY, FARXIGA, Fibroscan, GARDASIL 9, Kerendia, NURTEC ODT, OPSUMIT, OTEZLA, PULMONX CHARTIS TABLET CONSOLE, REPATHA, SHINGRIX, TZIELD, UPTRAVI, ZAVZPRET, ZENPEP, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error